| scholarly article | Q13442814 |
| P50 | author | Javier Cáceres Del Carpio | Q85499886 |
| Deepika Malik | Q87895372 | ||
| P2093 | author name string | Baruch D Kuppermann | |
| Claudio Ramirez | |||
| M Cristina Kenney | |||
| Mohamed Tarek | |||
| David Boyer | |||
| P2860 | cites work | Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results | Q24633874 |
| Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis | Q24684263 | ||
| Targeted deletion of Vegfa in adult mice induces vision loss | Q28513588 | ||
| Prevalence of age-related macular degeneration in the United States | Q29614964 | ||
| Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. | Q30824036 | ||
| Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells | Q33481665 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. | Q34557341 | ||
| Vascular endothelial growth factors and angiogenesis in eye disease | Q35070749 | ||
| The role of vascular endothelial growth factor in ocular health and disease | Q36029161 | ||
| Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions | Q37014678 | ||
| Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? | Q37976402 | ||
| Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review | Q38127832 | ||
| Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy | Q38302775 | ||
| Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells | Q39150034 | ||
| The effects of aflibercept on the viability and metabolism of ocular cells in vitro | Q39220888 | ||
| Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences | Q39357577 | ||
| Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. | Q42493511 | ||
| Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. | Q45927203 | ||
| Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells | Q46397980 | ||
| Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study | Q46969343 | ||
| Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. | Q52886344 | ||
| Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1. | Q54482424 | ||
| Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration | Q81609780 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| aflibercept | Q4689286 | ||
| P304 | page(s) | i11-16 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture | |
| P478 | volume | 98 Suppl 1 |
| Q33674476 | A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits |
| Q38761590 | Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. |
| Q36331045 | Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion |
| Q35657595 | Aflibercept: A Review of Its Use in Diabetic Macular Oedema |
| Q35903134 | Are biological agents toxic to human chondrocytes and osteocytes? |
| Q36835209 | Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion |
| Q47162407 | Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells |
| Q38874774 | Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell |
| Q37729097 | Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions. |
| Q33773175 | Effects of bevacizumab on endoplasmic reticulum stress in hypoxic retinal pigment epithelial cells |
| Q90713522 | Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria |
| Q59789197 | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| Q42002414 | Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF. |
| Q28075557 | Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept |
| Q97567741 | Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update |
| Q51697739 | Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits. |
| Q91842418 | Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes |
| Q40039608 | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. |
| Q37288622 | Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
| Q42588556 | Introduction. Treatment paradigms within the use of anti-VEGF agents |
| Q49694255 | MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regime |
| Q47162242 | One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion |
| Q37525339 | Osteonecrosis of the jaw associated with ziv-aflibercept |
| Q35238943 | Pharmacotherapy for treatment of retinal vein occlusion |
| Q42363696 | Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. |
| Q53098522 | Retinal and choroidal angiogenesis: a review of new targets. |
| Q58765111 | The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture |
| Q53134473 | Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. |
| Q46294818 | Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema. |
| Q35899591 | Ziv-aflibercept in macular disease |
Search more.